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Abstract
Background: Circulating hypermethylated RASSF1A could be a novel and potential useful marker for monitoring
patients with metastatic breast cancer. Technical obstacles include fragmentation of the circulating DNA, fluctuations in
the concentration, low concentrations of circulating tumor DNA, and different locations of methylation in the RASSF1A
gene among patients. One common method for detection of hypermethylated genes is sodium bisulfite conversion of
non-methylated cytosine to uracil, followed by detection with PCR. However, the method relies on full conversion of all
non-methylated cytosines, cause strand breaks, and loss of DNA. Alternatively, methylation-sensitive restriction enzymes
have been used to digest genomic DNA, as well as sodium bisulfite-treated DNA. By flanking different regions of the
RASSF1A with different PCR primer pairs, we analyzed for methylated genomic regions resistant to cleavage by the
methylation-sensitive restriction enzymes HpaII and BstUI. The goal was to find region(s) in RASSF1A with high
sensitivity and specificity that could be used for monitoring.
Results: The serum was spiked with non-human control DNA. By tracing the spiking control, the isolation
procedure of the rare circulating tumor DNA was initially optimized. By analysis of production of PCR amplicons from
HpaII- or BstUI-treated DNA isolated from 24 patients with metastatic breast cancer, we located four regions resulting
in sensitivities from 63 to 83 %. When examining samples from 24 control subjects, these four regions gave a specificity
of 100 %. Among these four regions, the primer pair with the highest PCR efficacy was selected to monitor the
RASSF1A concentration in 31 collected serum samples. The spiked DNA was then used to calculate the tumor
RASSF1A concentrations independent of fluctuations in circulating non-tumor DNA. As a proof of principle, there
was concordance in the kinetics of the RASSF1A and the serological cancer biomarkers CA 15-3, CEA, and TPA.
Conclusions: Methylation-sensitive restriction enzymes may be a useful methodological approach for monitoring
circulating hypermethylated RASSF1A among patients with metastatic breast cancer.
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Background
The clinical oncologist must assess and balance multiple
information obtained from physical examinations, im-
aging techniques, a broad pallet of biochemical labora-
tory tests in blood, as well as pathological examinations
of biopsies to make decisions whether the disease is
under control and the adverse effects are acceptable [1].
Among patients with metastatic breast cancer, sero-
logical tumor markers alone are not recommended for
monitoring the response to anticancer therapy [1]. An
area of development of a new generation of blood-based
cancer biomarkers for monitoring breast cancer patients
could be hypermethylated tumor suppressor genes [2].
The cytosine in the genes is methylated by endogenous
DNA methyltransferases with affinity for CpG dinucleo-
tide motifs. The CpG motifs are condensed in CpG
islands in the promoter regions, which are progressively
more densely methylated during tumorigenesis. One
method for detection of hypermethylated genes is so-
dium bisulfite conversion of non-methylated cytosine to
uracil [3]. Since methylated cytosine is protected from
conversion, primers and probes can then be designed to
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target hypermethylated genes, control genes, or regions
not susceptible to methylation by PCR amplification of
converted DNA [4]. However, the sodium bisulfite con-
version of the DNA may be incomplete [5] and cause
breaks in the DNA strands [6] and critical loss of total
sample DNA [7, 8]. These critical issues may comprom-
ise the analytical detection of hypermethylated genes.
One candidate gene for development of a novel bio-
marker could be the RAS association (RalGDS/AF-6)
domain family member 1A (RASSF1A) gene [9]. Close
examination of the methylation status of RASSF1A re-
veals that hypermethylation occurs in the promoter and
exon 1 region in a large percentage of human breast
cancers [10], but the distinct location of the methylated
CpGs are differentially distributed among different tu-
mors [11]. Methylation profiling of individual tumors
further suggests that DNA methylation progressively
spreads from the first exon into the promoter area of the
RASSF1A gene [11]. Furthermore, wide clonal intra-
tumor heterogeneity of promoter hypermethylation of
RASSF1A has been found in breast cancer [12]. Thus,
there are both intra- and interindividual differences in
the methylation profiles of the RASSF1A gene among tu-
mors from different patients. Thus, one primer and
probe design may not cover all types of RASSF1A
methylation profiles, and the patient-to-patient variation
may decrease the clinical sensitivity.
In a previous study, we used sodium bisulfite-
converted DNA and MethyLight to quantitate changes
in serial concentrations of the hypermethylated
RASSF1A in serum [13]. Serum samples were obtained
from 29 patients with advanced breast cancer undergo-
ing therapy and from 18 healthy control subjects [13].
Hypermethylated RASSF1A was not detected in serum
samples obtained from the healthy women but was de-
tected in all of the 29 patients at some time during mon-
itoring. Hypermethylated RASSF1A was detected in a
total of 45 % of the 422 serial patient samples. Thus,
RASSF1A was only periodically detected in some pa-
tients during monitoring. Furthermore, the collagen 2
A1 gene was used as a marker for the non-tumoral
DNA concentration in the serum sample primers and
used to normalize the RASSF1A concentration. However,
the non-tumoral DNA concentration may not be constant
in the blood due to a wide variety of confounding factors
[14–17]. The acute effect of therapy may also cause a
burst of DNA into the blood [18]. Thus, normalization of
circulating tumor DNA to non-tumoral DNA may give
false information regarding the status of the disease. Thus,
bisulfite conversion [5–8], normalization of tumoral DNA
to non-tumoral DNA [14–18], and one probe/primer de-
sign [10–12] may not be an optimal method for monitor-
ing hypermethylated DNA among patients with metastatic
breast cancer, as shown in the previous study [13].
In the present study, we have omitted the sodium bi-
sulfite treatment and changed the methodological pro-
cedure. Firstly, we spiked the serum samples with
external DNA. The spiking control was used to (1)
optimize the DNA isolation steps and (2) to express the
concentration of RASSF1A in nmol/ml. Thus, the con-
centration of hypermethylated RASSF1A was not de-
pending on the fluctuating non-tumoral control DNA.
Secondly, we used the restriction enzymes HpaII and
BstUI to cleave unmethylated 5′-CCGG and 5′-CGCG
motifs in the DNA to detect uncleaved hypermethylated
RASSF1A. Thirdly, we also tested different primer pairs
flanking different DNA regions of the RASSF1A gene to
encounter for the intra- and interbiological variation of
the methylation profile to ensure optimal sensitivity and
specificity. Finally, as a proof of principle, the primer
pair with the highest clinical sensitivity, specificity, and
PCR performance were used to monitor serial changes
in the concentrations of RASSF1A in serum obtained
from a patient with metastatic breast cancer during
therapy.
Results
Serum samples were obtained from 24 patients with
metastatic breast cancer and from 24 age-matched
healthy female as controls. The average concentrations
of the protein tumor markers cancer-antigen 15-3 (CA
15-3), carcinoembryonic antigen (CEA), and tissue poly-
peptide antigen (TPA) among patients and healthy fe-
males are shown in Table 1. The concentrations spanned
a wide range. The concentrations of CA 15-3, CEA, and
TPA were significantly higher in serum from breast cancer
patients as compared to the healthy females. In a few pa-
tients, the marker concentrations were below the cut of
level. One sample had a CEA concentrations <7.5 μg/ml
and two samples had a TPA concentration <357 U/L,
whereas all CA 15-3 concentrations were >30 kU/L. All
the healthy females had CA 15-3, CEA, and TPA concen-
trations below the respective cut of levels.
Table 1 Protein tumor marker concentrations among the investigated patients with metastatic breast cancer and healthy females
CA 15-3 (mean ± SE, n = 24) CEA (mean ± SE, n = 24) TPA (mean ± SE, n = 24)
Patients with metastatic breast cancer 1552 ± 384 kU/La 559.7 ± 177 μg/La 2639 ± 657 U/La
Age-matched healthy females 14.4 ± 1.1 kU/L 3.1 ± 0.3 μg/L 56.8 ± 10.8 U/L
aSignificantly different from age-matched control concentration (p < 0.05). The serum samples were used to isolate DNA, which was used to calculate the sensitivity and
specificity of six different primer designs against hypermethylated RASSF1A
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Six different primer pairs were designed against
RASSF1A promoter region and exon 1 (NG_02327.1,
region 4562-5517). The primers targeted different lo-
cations of the gene and targeted different numbers of
HpaII and BstUI cleaving motifs (Table 2). The investi-
gated RASSF1A sequence contained 88 CpG dinucleo-
tide sites, which may be aberrantly methylated as a
response to neoplasia. Among these sites, there are
seven HpaII and sixteen BstUI sites. The six designed
primer pairs covered six HpaII and fourteen BstUI
sites, covering 39 % of all CpG sites. The base pair
length of the designs was kept below <300 bp in order
to maximize the chance of amplifying fragmented
DNA [16].
To validate the six primer pairs, cDNA amplicons
were produced and mock-digested or incubated with
HpaII alone, or BstUI alone, respectively. Since PCR
amplicons are not methylated, all HpaII or BstUI cleav-
age motifs will be cleaved in the amplicons. The digest
was separated on 1× TBE ethidium-stained agarose gels,
as shown in Fig. 1. Primer pairs designed to contain ex-
clusively HpaII cleavage sites, BstUI sites, or both type
of cleavage sites, displayed a digestion profile as ex-
pected. However, the 288-bp amplicon produced with
primer 32 was calculated to be reduced to 279 bp after
BstUI cleavage. This minor reduction in base pair length
was not visually detectable by agarose-electrophoresis.
Productions of amplicons from HpaII- or BstUI-
treated serum DNA from 24 metastatic breast cancer
patients and 24 healthy controls were then used to cal-
culate the sensitivity and specificity. This was plotted in
a receiver operating characteristic (ROC) curve, as
shown in Fig. 2. When DNA was BstUI-treated and sub-
sequently PCR amplified with primer pair 66, amplicons
was detected in 20 of 24 serum samples (83 % sensitiv-
ity) isolated from metastatic breast cancer patients. In
contrast, no amplicons were produced when using DNA
isolated from serum obtained from 24 healthy females
(100 % specificity). This design targeting five BstUI sites
distal to the initiation site of RASSF1A gave the highest
AUC in the ROC plot relative to the eight other primer
combinations. Primer 50 HpaII, 54 BstUI, and 32 HpAII
had a clinical specificity of 100 %, but the sensitivity was
relatively lower, 71, 71, and 63 %, respectively.
Since monitoring require precise measurements of the
serial concentrations of rare tumor DNA, the four pri-
mer pairs with 100 % clinical specificity were then tested
for their analytical imprecision in terms of coefficient of
variation, PCR amplification factor, efficiency, linearity,
and limits of detection. As shown in Fig. 3, PCR amplifi-
cation with primer 50 developed a signal linear over a
106-fold change in DNA concentration, an amplification
factor of 1.98 and efficiency of 98.02 %. The analytical
coefficient of variation was 13.2 % (n = 30 determina-
tions), and the limit of detection was 0.01 ng/ml of
DNA. Overall, primer 50 was marginally superior to the
three other primer pairs and was selected to amplify
HpaII-treated DNA isolated from the serum samples.




The sequences of six different primer pairs designed against RASSF1A, the length of the amplicon, and the number of C↓CGG and CG↓CG sites for each primer
pair are shown in the upper panel
The lower panel shows the location of C↓CGG (solid line) and CG↓CG (broken line) cleavage sites in RASSF1A. The primer pairs were designed to target these
C↓CGG and CG↓CG sites. Methylation of the cytosine in the CpG dinucleotide motif within the C↓CGG and CG↓CG sites protects against enzymatic restriction
cutting by HpaII and BstUI, respectively, and enables formation of amplicons. Unmethylation results in digestion of the target and no formation of amplicons. The
location of the initiation site by the codon ATG is show by an arrow
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The average concentration of the hypermethylated
RASSF1A using all primer designs was plotted against
the serum concentrations of the tumor burden markers
CA 15-3 and CEA and the tumor activity marker TPA.
As shown in Fig. 4, there was a concordance of the
concentrations of TPA with the concentrations of the
hypermethylated RASSF1A. There was discordance of
the CA-15-3 and CEA concentrations with the hyper-
methylated RASSF1A concentrations.
As the first proof of principle, 31 independent serial
data for the tumor markers CA 15-3, CEA, TPA and
hypermethylated RASSF1A for one patient A is shown in
Fig. 5. Overall, there was concordance with the change
in tumor marker concentrations and the change in
RASSF1A concentrations.
Discussion
Hypermethylation of the RASSF1A gene is a prime candi-
date among many genes as a potential novel biomarker for
stage I–IV breast cancer and have been investigated for
early detection of cancer, diagnosis, prognosis for the pa-
tient, prediction of the effect of therapy, and monitoring of
the effect of therapy by measuring the circulating bio-
marker concentration (reviewed in [9]). In a previous study,
we monitored circulating hypermethylated RASSF1A and
showed concordance with the kinetics of CA 15-3, CEA,
and TPA but also the periodical lack of RASSF1A detection
in some patients with advanced breast cancer [13]. The
periodical lack of detection could be due to in situ sub-
detectable concentrations and/or due to an analytical
problem with sodium bisulfite conversion of fragmen-
ted DNA [13].
Fig. 1 HpaII and BstUI restriction fragments. PCR amplicons produced
with primer set 32, 40, 50, 54, 63, and 60 were incubated with HpaII or
BstUI restriction enzymes, or mock-digested (−). Since PCR amplicons
are not methylated, all HpaII and BstUI motifs sites are cleaved. The
DNA fragments were separated on an agarose gel and UV-illuminated
by ethidium bromide staining. Amplicons produced by primer pair 40
was exclusively cleaved by HpaII; primers 54 and 63 were only cleaved
by BstUI; and the amplicons produced by 32, 50, and 66 were cleaved
by both HpaII and BstUI. The BstUI cleavage of the amplicon produced
by primer pair 32 was calculated to reduce the length with 9 bp. This
minor reduction in length may not be visually detectable by agarose
gel electrophoresis
Fig. 2 ROC curve for detection of hypermethylated RASSF1A. Data plot
of the sensitivity and 100 % specificity. Serum DNA was isolated
from serum from 24 patients with metastatic breast cancer and 24
age-matched healthy control individuals. The DNA was incubated
with either the methylation-resistant restriction enzymes HpaII or
BstUI and thereafter PCR amplified with six different primer designs
(primer ID # 32, 40, 50, 54, 63, and 66, as explained in Table 2) covering
different regions of the promoter and exon 1 of RASSF1A
Fig. 3 Correlation of the Ct values and logarithmic DNA amplicons.
DNA was diluted sequentially tenfold and PCR amplified with primer
no. 50. Each measurement was performed as triplicates (mean ± SD).
Ct (cycle threshold) is defined as the number of cycles required for
the fluorescent signal to cross the threshold
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In the present study, we have optimized the steps for
isolating the rare serological tumor DNA fragments by
tracing a spiking control. Instead of using sodium bisul-
fite treatment of DNA, we used restriction enzymes;
these are sensitive to methylation of the CpG motif in
the cleavage site. By using restriction enzyme-treated as
DNA template, flanking primer pairs were used to amp-
lify different locations of RASSF1A. The different designs
were tested for optimal sensitivity, specificity, and PCR
performance. With this method, we found a sensitivity
of 63–83 % at a specificity of 100 % when testing 24
cross-sectional samples collected from metastatic breast
patients and healthy females.
In the four previous cross-sectional studies of sodium
bisulfite-converted DNA, the circulating hypermethy-
lated RASSF1A was detected in metastatic breast cancer
patients [19–22]. Tan et al. [19] detected RASSF1A in
42 % (8 out of 19) of the serum samples with a
Fig. 4 Correlation between the concentrations of the protein tumor markers and hypermethylated RASSF1A based on the cross-sectional samples
from each of the 24 patients. The serum concentration of CA 15-3 (a), CEA (b), and TPA (c) are plotted against the average hypermethylated
RASSF1A concentration determined by using all six primer designs. The data was obtained from 24 serum samples collected from patients with
metastatic breast cancer
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technique based on methylation-specific PCR of sodium
bisulfite-converted DNA. The other studies [20, 21] both
used the MethyLight PCR technique but with different
primers and probes raised against sodium bisulfite-
converted DNA. Matuschek et al. [20] detected
RASSF1A in 43 % (10 out of 23) of the serum samples,
whereas Van der Auwera et al. [21] detected 35 % (28
out of 79). Fackler et al. [22] used the cMethDNA assay
to determine the concentrations of ten individual genes.
The assay is depending on the input of sodium bisulfite-
converted DNA, which are amplified in two sequential
PCR reactions; first, multiplex PCR amplification of the
Fig. 5 Monitoring of patient A with metastatic breast cancer during therapy. Three panels with serial concentrations of the protein biomarkers CA
15-3, CEA, TPA and the concentrations of hypermethylated RASSF1A
Kristiansen et al. Clinical Epigenetics  (2016) 8:35 Page 6 of 9
ten genes with external primers, then followed by quan-
tification of individual genes by real-time methylation-
specific PCR reaction. Detection of RASSF1A alone was
achieved in 70 % (40 out of 57) of the training and test
samples, but the sensitivity was raised to 91 % at a speci-
ficity of 96 % when combining the panel of genes. Taken
together, in these studies using different methods, but
bisulfite-converted DNA, the sensitivity was in the range
of 35–70 % [19–22]. In the present study, using input of
genomic DNA, two different methylation-sensitive re-
striction enzymes, the sensitivity was 63–80 % at a speci-
ficity of 100 % for four different regions of RASSF1A. In
contrast, the low sensitivities for detection of RASSF1A
in the other studies could be due sodium bisulfite con-
version of DNA, which may limit the amount of the rare
tumor DNA [19–21, 23]. Thus, detection of genes in a
panel with methylation-sensitive restriction enzyme-
digested DNA as assay input should be further
investigated.
The large span and variations in the CA 15-3, CEA,
and TPA concentrations among the cross-sectional sam-
ples were used to test for correlation between the pro-
tein biomarkers and hypermethylated RASSF1A
concentrations (Fig. 4). The CA 15-3 assay is based on
the monoclonal antibodies 115D8 and DF3 which are
both raised against the human MUC1 protein. The CEA
molecule is a glycoprotein involved in cell adhesion; it is
a glycosylphosphatidylinositol cell surface anchored
glycoprotein that is released in to the bloodstream of
cancer patients and healthy individuals. Being a
secretory product, both CA 15-3 and CEA are consid-
ered as serological markers of changing tumor burden in
the individual patient. TPA belongs to the cytoskeleton
proteins circulating as a complex of soluble proteolytic
polypeptide fragments of cytokeratins 8, 18, and 19. The
TPA release may indicate cell turnover and the informa-
tion supplied by the TPA may be distinctly different
from the information supplied by the markers of tumor
burden CA 15-3 and CEA [24]. As shown in Fig. 4, the
present preliminary results may suggest that circulating
hypermethylated RASSF1A may be a biomarker for cell
turnover and/or cell death by apoptosis/necrosis. How-
ever, as shown in Fig. 5, we found concordance with
hypermethylated RASSF1A with the kinetics of CA 15-3,
CEA, and TPA. This may be due to the similar kinetics
of the three markers CA 15-3, CEA, and TPA.
Monitoring of the changes in serial biomarker concen-
tration requires an analytical method with a low-as-
possible analytical coefficient of variation [25]. When the
concentration of circulating tumor DNA is expressed
relatively to the circulating non-tumor DNA, the change
in concentration may be misleading. In the present
study, we used a spiking control to account for small
pre-analytical variations in the DNA concentrations.
Spiking of serum samples has previously been used by
Fackler et al. [22] to facilitate quantification of tumor
DNA. The optimal location in the RASSF1A gene and
PCR performance were then used to monitor metastatic
breast cancer patients during therapy. As a proof of
principle, 31 serial samples were monitored with the
tumor markers CA 15-3, CEA, and TPA and compared
with the changes in the hypermethylated RASSF1A con-
centrations. In the present study, and in the previous
study [13], concordance could be observed between ser-
ial changes of the hypermethylated RASSF1A gene and
the protein markers.
Conclusion
In conclusion, it is suggested to use methylation-
sensitive restrictive enzymes as an alternative to the
time-consuming sodium bisulfite step, which also may
reduce the amount of tumor DNA. Circulating hyper-
methylated RASSF1A and protein markers may have
similar kinetics during monitoring. Future studies are re-
quired to define criteria for changes in tumor DNA to
assess the disease status. These criteria should be used




Women among the healthy staff at the Departments of
Oncology and Clinical Chemistry, Herlev Hospital,
University of Copenhagen, Denmark, volunteered to par-
ticipate in the study from 1990 to 1992 [26]. All subjects
gave informed consent to their participation, and the
study was approved by the regional Ethical Committee
(KA 93076). All subjects stated they were free of disease
at the time of the study, and none had any known
chronic or recurrent illness or was taking any medica-
tion. The subjects continued their usual lifestyle during
the period of the study. No investigations were per-
formed to exclude asymptomatic breast cancer. Serum
samples was stored at −80 °C and later used for detec-
tion of hypermethylated RASSF1A.
Patients with metastatic breast cancer
The investigated patients had histologically proven ad-
vanced progressive breast cancer (stage IV) with measur-
able or evaluable disease [26, 27]. They received
epirubicin 70 mg/m2 on days 1 and 8 every 4 weeks.
Epirubicin was continued until progressive disease (PD)
was noted or until a maximum cumulative dose of
1000 mg/m2 had been administered. Clinical response
evaluations at that time of the study (1988 to 1991) were
based on the criteria of the World Health Organization
[28] and performed by investigators without knowledge
of the tumor marker data. Blood specimens for CA 15-3,
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CEA, and TPA analysis were sampled before each treat-
ment cycle [26, 27]. At each sampling, the serum speci-
men used for analysis of the protein tumor markers was
saved in different aliquots at −80 °C and used for the
current analysis of hypermethylated DNA. The study
complied with the Helsinki II Declaration and was ap-
proved by the Scientific Ethics Committee of
Copenhagen County (KA 89257, H-D-2009-048).
Isolation of tumor DNA
One milliliter of serum from the bio bank was quick-
thawed and spiked with a constant amount of PBR322
plasmid (Life Technologies). The spiking control was
traced during all the isolation steps. The spiked serum
was immediately transferred to 1 ml of binding buffer
supplemented with RNA carrier. The DNA isolation was
carried out as suggested by Roche Diagnostics (High
Pure Viral Nucleic Acid Large Volume Kit), except that
the DNA and tracer were eluted with 0.1 ml of Tango
buffer (Fisher Scientific). The DNA capturing efficiency
of column filters was investigated by repassing the sam-
ple DNA on the columns. One DNA capturing cycle was
found sufficient (data not shown). The eluting efficiency
of the captured DNA from the filters was investigated by
eluting filters with different volumes of elute buffer
(buffer suggested by the manufacturer), water, or Tango
buffer. The optimal method was to elute the DNA from
filters with 100 μl of Tango buffer. There was no differ-
ence between the recovery and relative concentration of
human DNA versus the spiking control plasmid. Conse-
quently, the spiking control could be used to normalize
for small fluctuations in DNA recovery. Twenty microli-
ters of eluted DNA was added to 10 U of BstUI or HpaII
(Fisher Scientific). Samples were incubated for 16 h at
37 °C followed by 20 min at 95 °C. The digested DNA
sample was added 10× volume of DNA-free water
(Sigma-Aldrich) and stored at −20 °C.
Detection of hypermethylated RASSF1A
The detection of hypermethylated RASSF1A was based on
the restriction enzymes HpaII and BstUI that cleaves
unmethylated 5′-CCGG and 5′-CGCG motifs, respect-
ively [29]. Notably, methylations of CpG in the cleavage
motifs remain intact and detectable by real-time PCR. The
PCR amplifications were done in duplicates of 20 μl each
containing 250 pmol/L of primer using the Power SYBR
Green PCR Master Kit (Life Technologies). The PCR was
carried out on a 7500 Fast Real-Time PCR apparatus
(Applied Biosystems). The inhibitory effect of interfering
Mg++ from the Tango buffer on PCR amplification process
was investigated. A final concentration of 3 % Tango buf-
fer was found to have no influence on the efficiency of the
PCR amplification. A primer set was designed against the
spiking control to cover HpaII and BstUI cleavage motifs.
This primer set was used to validate for 100 % cleavage ef-
ficiency of all DNA samples. A time-course study revealed
that all PCR amplicons and the spiking control were
100 % cut after 2 h of incubation at 37 °C. As a standard,
the incubation time was set to 16 h. Furthermore, a
restriction-insensitive primer set was designed against a
DNA region in the spiking control that did not contain
HpaII and BstUI cleavage motifs. After PCR amplification
of HpaII- or BstUI-pretreated DNA, the original serum
concentration of hypermethylated RASSF1A was then
expressed in ng/ml by using a DNA standard curve and
with minor corrections for changes in DNA recovery.
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